Alberto Paradela
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alberto Paradela has a total of 517 co-authors. Here are the top co-authors by number of shared publications:
- Fernando J. Corrales
Functional Proteomics Laboratory, Centro Nacional de Biotecnología-CSIC, Madrid, Spain
17 shared publications - Miguel Marcilla
Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain
11 shared publications - Rosana Navajas
Laboratorio de Proteómica, Centro Nacional de Biotecnología, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain
10 shared publications Juan Pablo Albar
Proteomics Unit, Spanish National Biotechnology Centre (CSIC), Darwin 3, 28049 Madrid, Spain
9 shared publications- Carlos A. Jerez
Laboratory of Molecular Microbiology and Biotechnology, Department of Biology, Faculty of Sciences, University of Chile, Santiago 7800003, Chile
7 shared publications - Juan Pablo Albar
Proteomics Laboratory, National Biotechnology Center, Madrid, Spain
6 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by American Dairy Science Association in Journal of Dairy Science
- Vol. 109 (11) , 11308-11319
Qualitative and quantitative analysis of mixed-milk cheeses by targeted proteomics
This work presents a novel analytical method to determine the proportions of cow, sheep, and goat milk in mixed-milk cheeses, common in Spain and Europe. First, an in-depth shotgun proteomic analysis to define the protein composition of milk and cheese from each species was performed. Thereafter, a targeted parallel reaction monitoring method was developed using a panel of 3 species-specific tryptic peptides and one peptide common to all species. This method was optimized using reference cheeses of known composition, and it was validated according to internationally recognized guidelines. The method demonstrated linearity in the range of = 0% to 100% with detection limits less than 1% for all 3 species and showed good repeatability (CV = 8%), reproducibility (CV = 10%), and accuracy (99.6%), enabling both qualitative and quantitative analysis. Finally, the method was applied to commercial cheeses with diverse compositions and ripening times. The measurements were unaffected by either the ripening or production process, demonstrating the robustness of the analysis even with potential interferents. These results demonstrate the great potential of the method for quality control purposes and its applicability to real-world commercial samples.
- 1 November 2026
- Published by American Dairy Science Association in Journal of Dairy Science
- Vol. 109 (11) , 11308-11319
Open AccessQualitative and quantitative analysis of mixed-milk cheeses by targeted proteomics
This work presents a novel analytical method to determine the proportions of cow, sheep, and goat milk in mixed-milk cheeses, common in Spain and Europe. First, an in-depth shotgun proteomic analysis to define the protein composition of milk and cheese from each species was performed. Thereafter, a targeted parallel reaction monitoring method was developed using a panel of 3 species-specific tryptic peptides and one peptide common to all species. This method was optimized using reference cheeses of known composition, and it was validated according to internationally recognized guidelines. The method demonstrated linearity in the range of = 0% to 100% with detection limits less than 1% for all 3 species and showed good repeatability (CV = 8%), reproducibility (CV = 10%), and accuracy (99.6%), enabling both qualitative and quantitative analysis. Finally, the method was applied to commercial cheeses with diverse compositions and ripening times. The measurements were unaffected by either the ripening or production process, demonstrating the robustness of the analysis even with potential interferents. These results demonstrate the great potential of the method for quality control purposes and its applicability to real-world commercial samples.
- Open Access
Decoding the Cellular Response to Methylthioadenosine Uncovers Novel Targets for Chronic Liver Disease
Progressive familial intrahepatic cholestasis type 3 (PFIC3), caused by MDR3 deficiency (MDR2 in mice), is a lethal pediatric liver disease characterized by early-onset persistent cholestasis, progressive fibrosis, cirrhosis, and eventual liver failure. MDR3 is a phosphatidylcholine transporter located in the canalicular membrane of hepatocytes, and its deficiency leads to the accumulation of free bile acids, which damage epithelial cells due to their detergent-like effect. Therapeutic options remain limited, highlighting the need to identify molecular drivers of disease progression and novel pharmacological strategies. To investigate the molecular alterations associated with this deficiency, our laboratory performed functional proteomic analyses in patient samples and murine hepatic organoids, revealing consistent reprogramming of one-carbon metabolism (OCM). Based on these findings, we explored the therapeutic potential and molecular mechanisms of 5′-methylthioadenosine (MTA), a metabolite involved in this pathway. Using hepatocellular carcinoma cells (PLCs), we combined quantitative shotgun proteomics with the proteome integral solubility alteration (PISA) assay to characterize functional responses and identify direct protein targets of MTA. To reinforce the physiological relevance of our findings, we extended the PISA analysis to liver protein extracts from the Mdr2−/− mouse model of chronic cholestatic injury, enabling validation of candidate target interactions observed in cellular extracts. Proteomic profiling revealed that MTA induces significant alterations in cell division processes, epigenetic regulatory networks, and energy metabolism, thereby promoting an adaptive phenotype characterized by metabolic plasticity, microenvironmental reorganization, and immunomodulation. These findings provide a robust molecular framework for understanding the hepatic response to MTA and shed new light on the mechanisms that may underlie its beneficial effects. In addition, they provide a valuable platform for further investigation of the therapeutic potential of this compound and its prospective translation into clinical practice.
Open AccessDecoding the Cellular Response to Methylthioadenosine Uncovers Novel Targets for Chronic Liver Disease
Progressive familial intrahepatic cholestasis type 3 (PFIC3), caused by MDR3 deficiency (MDR2 in mice), is a lethal pediatric liver disease characterized by early-onset persistent cholestasis, progressive fibrosis, cirrhosis, and eventual liver failure. MDR3 is a phosphatidylcholine transporter located in the canalicular membrane of hepatocytes, and its deficiency leads to the accumulation of free bile acids, which damage epithelial cells due to their detergent-like effect. Therapeutic options remain limited, highlighting the need to identify molecular drivers of disease progression and novel pharmacological strategies. To investigate the molecular alterations associated with this deficiency, our laboratory performed functional proteomic analyses in patient samples and murine hepatic organoids, revealing consistent reprogramming of one-carbon metabolism (OCM). Based on these findings, we explored the therapeutic potential and molecular mechanisms of 5′-methylthioadenosine (MTA), a metabolite involved in this pathway. Using hepatocellular carcinoma cells (PLCs), we combined quantitative shotgun proteomics with the proteome integral solubility alteration (PISA) assay to characterize functional responses and identify direct protein targets of MTA. To reinforce the physiological relevance of our findings, we extended the PISA analysis to liver protein extracts from the Mdr2−/− mouse model of chronic cholestatic injury, enabling validation of candidate target interactions observed in cellular extracts. Proteomic profiling revealed that MTA induces significant alterations in cell division processes, epigenetic regulatory networks, and energy metabolism, thereby promoting an adaptive phenotype characterized by metabolic plasticity, microenvironmental reorganization, and immunomodulation. These findings provide a robust molecular framework for understanding the hepatic response to MTA and shed new light on the mechanisms that may underlie its beneficial effects. In addition, they provide a valuable platform for further investigation of the therapeutic potential of this compound and its prospective translation into clinical practice.
- Open Access
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (4) , 2183-2192
Targeted Quantitative Analysis of Specific Proteins in Cytosolic, Mitochondrial, and Nuclear Fractions Using PRM
Mitochondria play a central role in liver physiology by regulating key metabolic processes. Consequently, mitochondrial dysfunction is a hallmark of multiple liver diseases, including steatosis, steatohepatitis, and liver failure following hepatectomy. Subcellular fractionation is widely used to isolate mitochondria from liver cells or tissue; however, the enrichment and purity of isolated fractions are critical to ensure reliable downstream functional and proteomic analyses. Conventional validation methods, such as immunoblotting of organelle-specific markers, are limited by low throughput, restricted sensitivity, and variability. In this study, we present a targeted proteomics strategy based on parallel reaction monitoring (PRM) to quantitatively assess the enrichment of cytosolic, mitochondrial, and nuclear fractions obtained from liver samples using commercial isolation kits. PRM analyses demonstrated robust and compartment-specific enrichment in both PLC/PRF/5 cells and mouse liver tissue. In PLC/PRF/5 cells, high nuclear/cytosolic enrichment was observed for Prelamin A/C, while mitochondrial markers such as ATPase showed strong mitochondrial/cytosolic ratios. Cytosolic markers consistently displayed enrichment in the cytosolic fraction. Similar trends were observed in mouse liver tissue, confirming applicability across biological systems. Overall, these results highlight PRM as a sensitive, reproducible, and cost-effective alternative to immunodetection approaches for evaluating subcellular fraction purity, supporting high-quality mitochondrial preparations for translational hepatology studies.
- 25 February 2026
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 25 (4) , 2183-2192
Open AccessTargeted Quantitative Analysis of Specific Proteins in Cytosolic, Mitochondrial, and Nuclear Fractions Using PRM
Mitochondria play a central role in liver physiology by regulating key metabolic processes. Consequently, mitochondrial dysfunction is a hallmark of multiple liver diseases, including steatosis, steatohepatitis, and liver failure following hepatectomy. Subcellular fractionation is widely used to isolate mitochondria from liver cells or tissue; however, the enrichment and purity of isolated fractions are critical to ensure reliable downstream functional and proteomic analyses. Conventional validation methods, such as immunoblotting of organelle-specific markers, are limited by low throughput, restricted sensitivity, and variability. In this study, we present a targeted proteomics strategy based on parallel reaction monitoring (PRM) to quantitatively assess the enrichment of cytosolic, mitochondrial, and nuclear fractions obtained from liver samples using commercial isolation kits. PRM analyses demonstrated robust and compartment-specific enrichment in both PLC/PRF/5 cells and mouse liver tissue. In PLC/PRF/5 cells, high nuclear/cytosolic enrichment was observed for Prelamin A/C, while mitochondrial markers such as ATPase showed strong mitochondrial/cytosolic ratios. Cytosolic markers consistently displayed enrichment in the cytosolic fraction. Similar trends were observed in mouse liver tissue, confirming applicability across biological systems. Overall, these results highlight PRM as a sensitive, reproducible, and cost-effective alternative to immunodetection approaches for evaluating subcellular fraction purity, supporting high-quality mitochondrial preparations for translational hepatology studies.
- Open Access
- 19 February 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 42, 113-119
Multiple mechanisms drive linezolid resistance in clinical Enterococcus faecium isolates by increasing poxtA gene expression
- 19 February 2025
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 42, 113-119
Open AccessMultiple mechanisms drive linezolid resistance in clinical Enterococcus faecium isolates by increasing poxtA gene expression
- Open Access
- 4 September 2024
- Published by Wiley in Molecular Microbiology
- Vol. 122 (5) , 797-818
In Vivo Cross‐Linking Sheds Light on the Salmonella Divisome in Which PBP3 and PBP3SAL Compete for Occupancy
Bacterial cell division is orchestrated by proteins that assemble in dynamic complexes collectively known as the divisome. Essential monofunctional enzymes with glycosyltransferase or transpeptidase (TPase) activities, FtsW and FtsI respectively, engage in the synthesis of septal peptidoglycan (sPG). Enigmatically, Salmonella has two TPases that can promote cell division independently: FtsI (PBP3) and the pathogen‐specific paralogue PBP3SAL. How Salmonella regulates the assembly of the sPG synthase complex with these two TPases, is unknown. Here, we characterized Salmonella division complexes in wild‐type cells and isogenic mutants lacking PBP3 or PBP3SAL. The complexes were cross‐linked in vivo and pulled down with antibodies recognizing each enzyme. Proteomics of the immunoprecipitates showed that PBP3 and PBP3SAL do not extensively cross‐link in wild type cells, supporting the presence of independent complexes. More than 40 proteins cross‐link in complexes in which these two TPases are present. Those identified with high scores include FtsA, FtsK, FtsQLB, FtsW, PBP1B, SPOR domain‐containing proteins (FtsN, DedD, RlpA, DamX), amidase activators (FtsX, EnvC, NlpD) and Tol‐Pal proteins. Other cross‐linked proteins are the protease Prc, the elongasome TPase PBP2 and, D,D‐endo‐ and D,D‐carboxypeptidases. PBP3 and PBP3SAL localize at midcell and compete for occupying the division complex in response to environmental cues. Thus, a catalytic‐dead PBP3SAL‐S300A variant impairs cell division in a high osmolarity and acidic condition in which it is produced at levels exceeding those of PBP3. Salmonella may therefore exploit an ‘adjustable’ divisome to exchange TPases for ensuring cell division in distinct environments and, in this manner, expand its colonization capacities.
- 4 September 2024
- Published by Wiley in Molecular Microbiology
- Vol. 122 (5) , 797-818
Open AccessIn Vivo Cross‐Linking Sheds Light on the Salmonella Divisome in Which PBP3 and PBP3SAL Compete for Occupancy
Bacterial cell division is orchestrated by proteins that assemble in dynamic complexes collectively known as the divisome. Essential monofunctional enzymes with glycosyltransferase or transpeptidase (TPase) activities, FtsW and FtsI respectively, engage in the synthesis of septal peptidoglycan (sPG). Enigmatically, Salmonella has two TPases that can promote cell division independently: FtsI (PBP3) and the pathogen‐specific paralogue PBP3SAL. How Salmonella regulates the assembly of the sPG synthase complex with these two TPases, is unknown. Here, we characterized Salmonella division complexes in wild‐type cells and isogenic mutants lacking PBP3 or PBP3SAL. The complexes were cross‐linked in vivo and pulled down with antibodies recognizing each enzyme. Proteomics of the immunoprecipitates showed that PBP3 and PBP3SAL do not extensively cross‐link in wild type cells, supporting the presence of independent complexes. More than 40 proteins cross‐link in complexes in which these two TPases are present. Those identified with high scores include FtsA, FtsK, FtsQLB, FtsW, PBP1B, SPOR domain‐containing proteins (FtsN, DedD, RlpA, DamX), amidase activators (FtsX, EnvC, NlpD) and Tol‐Pal proteins. Other cross‐linked proteins are the protease Prc, the elongasome TPase PBP2 and, D,D‐endo‐ and D,D‐carboxypeptidases. PBP3 and PBP3SAL localize at midcell and compete for occupying the division complex in response to environmental cues. Thus, a catalytic‐dead PBP3SAL‐S300A variant impairs cell division in a high osmolarity and acidic condition in which it is produced at levels exceeding those of PBP3. Salmonella may therefore exploit an ‘adjustable’ divisome to exchange TPases for ensuring cell division in distinct environments and, in this manner, expand its colonization capacities.
- Open Access
TAF1-dependent transcriptional dysregulation underlies multiple sclerosis
A major conceptual and clinical challenge in multiple sclerosis (MS) is understanding the mechanisms that drive the central nervous system (CNS)-resident neuroinflammation and neurodegeneration underneath disease progression. Genome-wide association studies (GWAS) have implicated RNA polymerase II (RNAPII) promoter-proximal pausing in oligodendrocyte pathology, but the causal mechanisms remain unclear. Here we find that the C-terminal region of TAF1, a core component of the general transcription factor TFIID, is underdetected in progressive MS brains, which can be explained by endoproteolysis due to extralysosomal cathepsin B (CTSB). Mice lacking the C-terminal TAF1 domain (Taf1d38) exhibit MS-like brain transcriptomic signature, alongside CNS-resident inflammation, progressive demyelination, and motor disability. Mechanistically, C-terminal TAF1 interacts with MS-linked factors that cooperate to regulate RNAPII pausing, particularly affecting oligodendroglial myelination genes. These findings uncover a previously unrecognized transcriptional mechanism underlying MS progression and establish a tractable in vivo model for therapeutic development.
Open AccessTAF1-dependent transcriptional dysregulation underlies multiple sclerosis
A major conceptual and clinical challenge in multiple sclerosis (MS) is understanding the mechanisms that drive the central nervous system (CNS)-resident neuroinflammation and neurodegeneration underneath disease progression. Genome-wide association studies (GWAS) have implicated RNA polymerase II (RNAPII) promoter-proximal pausing in oligodendrocyte pathology, but the causal mechanisms remain unclear. Here we find that the C-terminal region of TAF1, a core component of the general transcription factor TFIID, is underdetected in progressive MS brains, which can be explained by endoproteolysis due to extralysosomal cathepsin B (CTSB). Mice lacking the C-terminal TAF1 domain (Taf1d38) exhibit MS-like brain transcriptomic signature, alongside CNS-resident inflammation, progressive demyelination, and motor disability. Mechanistically, C-terminal TAF1 interacts with MS-linked factors that cooperate to regulate RNAPII pausing, particularly affecting oligodendroglial myelination genes. These findings uncover a previously unrecognized transcriptional mechanism underlying MS progression and establish a tractable in vivo model for therapeutic development.
- Open Access
Harnessing homeostatically active RhoC at cell junctions preserves human endothelial barrier function during inflammation
Rho GTPases are molecular targets of bacterial toxins that modulate their enzymatic activity. RhoA, RhoB and RhoC are almost identical and play critical roles in generating actomyosin-mediated contractile forces that cause endothelial hyperpermeability during inflammation. Searching for new treatments to modulate endothelial integrity, we demonstrate that the specific and simultaneous activation of these three Rho GTPases with a chimeric recombinant toxin does not induce cell contraction but enhances homeostatic endothelial barrier function, increases reticular adherens junctions and preserves the microvascular endothelium in response to pathological inflammatory challenges in vitro and in vivo . This pro-barrier effect is specifically mediated by RhoC, whose activity is increased by cell confluence. The uniqueness of RhoC relies on an arginine 188 within its hypervariable region that determines its junctional localization, high homeostatic activity, and barrier-protective function. Quantitative proteomics revealed that RhoC regulates the expression of myosin light chain proteins and junction-stabilizing actomyosin. Thus, harnessing the activity of RhoC represents a potential therapy for strengthening endothelial barriers during pathological inflammation.
Open AccessHarnessing homeostatically active RhoC at cell junctions preserves human endothelial barrier function during inflammation
Rho GTPases are molecular targets of bacterial toxins that modulate their enzymatic activity. RhoA, RhoB and RhoC are almost identical and play critical roles in generating actomyosin-mediated contractile forces that cause endothelial hyperpermeability during inflammation. Searching for new treatments to modulate endothelial integrity, we demonstrate that the specific and simultaneous activation of these three Rho GTPases with a chimeric recombinant toxin does not induce cell contraction but enhances homeostatic endothelial barrier function, increases reticular adherens junctions and preserves the microvascular endothelium in response to pathological inflammatory challenges in vitro and in vivo . This pro-barrier effect is specifically mediated by RhoC, whose activity is increased by cell confluence. The uniqueness of RhoC relies on an arginine 188 within its hypervariable region that determines its junctional localization, high homeostatic activity, and barrier-protective function. Quantitative proteomics revealed that RhoC regulates the expression of myosin light chain proteins and junction-stabilizing actomyosin. Thus, harnessing the activity of RhoC represents a potential therapy for strengthening endothelial barriers during pathological inflammation.
- Open Access
- 10 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
ICAM-1 nanoclusters regulate hepatic epithelial cell polarity by leukocyte adhesion-independent control of apical actomyosin
Epithelial intercellular adhesion molecule (ICAM)-1 is apically polarized, interacts with, and guides leukocytes across epithelial barriers. Polarized hepatic epithelia organize their apical membrane domain into bile canaliculi and ducts, which are not accessible to circulating immune cells but that nevertheless confine most of ICAM-1. Here, by analyzing ICAM-1_KO human hepatic cells, liver organoids from ICAM-1_KO mice and rescue-of-function experiments, we show that ICAM-1 regulates epithelial apicobasal polarity in a leukocyte adhesion-independent manner. ICAM-1 signals to an actomyosin network at the base of canalicular microvilli, thereby controlling the dynamics and size of bile canalicular-like structures. We identified the scaffolding protein EBP50/NHERF1/SLC9A3R1, which connects membrane proteins with the underlying actin cytoskeleton, in the proximity interactome of ICAM-1. EBP50 and ICAM-1 form nano-scale domains that overlap in microvilli, from which ICAM-1 regulates EBP50 nano-organization. Indeed, EBP50 expression is required for ICAM-1-mediated control of BC morphogenesis and actomyosin. Our findings indicate that ICAM-1 regulates the dynamics of epithelial apical membrane domains beyond its role as a heterotypic cell–cell adhesion molecule and reveal potential therapeutic strategies for preserving epithelial architecture during inflammatory stress.
- 10 April 2024
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessICAM-1 nanoclusters regulate hepatic epithelial cell polarity by leukocyte adhesion-independent control of apical actomyosin
Epithelial intercellular adhesion molecule (ICAM)-1 is apically polarized, interacts with, and guides leukocytes across epithelial barriers. Polarized hepatic epithelia organize their apical membrane domain into bile canaliculi and ducts, which are not accessible to circulating immune cells but that nevertheless confine most of ICAM-1. Here, by analyzing ICAM-1_KO human hepatic cells, liver organoids from ICAM-1_KO mice and rescue-of-function experiments, we show that ICAM-1 regulates epithelial apicobasal polarity in a leukocyte adhesion-independent manner. ICAM-1 signals to an actomyosin network at the base of canalicular microvilli, thereby controlling the dynamics and size of bile canalicular-like structures. We identified the scaffolding protein EBP50/NHERF1/SLC9A3R1, which connects membrane proteins with the underlying actin cytoskeleton, in the proximity interactome of ICAM-1. EBP50 and ICAM-1 form nano-scale domains that overlap in microvilli, from which ICAM-1 regulates EBP50 nano-organization. Indeed, EBP50 expression is required for ICAM-1-mediated control of BC morphogenesis and actomyosin. Our findings indicate that ICAM-1 regulates the dynamics of epithelial apical membrane domains beyond its role as a heterotypic cell–cell adhesion molecule and reveal potential therapeutic strategies for preserving epithelial architecture during inflammatory stress.
- Open Access
- 15 March 2024
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 23 (4) , 1433-1442
Molecular Insights of Cholestasis in MDR2 Knockout Murine Liver Organoids
MDR3 (multidrug resistance 3) deficiency in humans (MDR2 in mice) causes progressive familial intrahepatic cholestasis type 3 (PFIC3). PFIC3 is a lethal disease characterized by an early onset of intrahepatic cholestasis progressing to liver cirrhosis, a preneoplastic condition, putting individuals at risk of hepatocellular carcinoma (HCC). Hepatocyte-like organoids from MDR2-deficient mice (MDR2KO) were used in this work to study the molecular alterations caused by the deficiency of this transporter. Proteomic analysis by mass spectrometry allowed characterization of 279 proteins that were differentially expressed in MDR2KO compared with wild-type organoids. Functional enrichment analysis indicated alterations in three main cellular functions: (1) interaction with the extracellular matrix, (2) remodeling intermediary metabolism, and (3) cell proliferation and differentiation. The affected cellular processes were validated by orthogonal molecular biology techniques. Our results point to molecular mechanisms associated with PFIC3 that may drive the progression to liver cirrhosis and HCC and suggest proteins and cellular processes that could be targeted for the development of early detection strategies for these severe liver diseases.
- 15 March 2024
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 23 (4) , 1433-1442
Open AccessMolecular Insights of Cholestasis in MDR2 Knockout Murine Liver Organoids
MDR3 (multidrug resistance 3) deficiency in humans (MDR2 in mice) causes progressive familial intrahepatic cholestasis type 3 (PFIC3). PFIC3 is a lethal disease characterized by an early onset of intrahepatic cholestasis progressing to liver cirrhosis, a preneoplastic condition, putting individuals at risk of hepatocellular carcinoma (HCC). Hepatocyte-like organoids from MDR2-deficient mice (MDR2KO) were used in this work to study the molecular alterations caused by the deficiency of this transporter. Proteomic analysis by mass spectrometry allowed characterization of 279 proteins that were differentially expressed in MDR2KO compared with wild-type organoids. Functional enrichment analysis indicated alterations in three main cellular functions: (1) interaction with the extracellular matrix, (2) remodeling intermediary metabolism, and (3) cell proliferation and differentiation. The affected cellular processes were validated by orthogonal molecular biology techniques. Our results point to molecular mechanisms associated with PFIC3 that may drive the progression to liver cirrhosis and HCC and suggest proteins and cellular processes that could be targeted for the development of early detection strategies for these severe liver diseases.